Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Klinic vs Revive Meds

Klinic
Graded #312

Higher grade

vs+3.8999999999999986
Revive Meds
Graded #404

Lower grade

The verdict

Klinic takes it — 60.8/100 to 56.9/100.

Klinic grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Klinic is a LegitScript-certified multi-condition telehealth platform prescribing brand-name GLP-1 medications—Wegovy (semaglutide) and Zepbound (tirzepatide)—to patients across all 50 U.S.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKlinic +24
45
21
Dose & formulationRevive Meds +11
53
64
Clinical oversightRevive Meds +1
79
80
Labs & monitoringKlinic +12
64
52
FulfillmentRevive Meds +14
76
90
Contract termsKlinic +2
55
53
Klinic · left barRevive Meds · right bar

The numbers

MetricKlinicRevive Meds
WeighScore60.8/10056.9/100
GradeCC
Scorecard rank#312#404
SemaglutideNot disclosed$369/mo (starting dose, compounded)
TirzepatideNot disclosed$459/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Klinic

Graded #312 · C

Strengths

  • LegitScript certified, licensed in all 50 states, DEA registered, HIPAA/SOC 2 Type II compliant
  • Broad insurance acceptance including Medicare, Medicaid, BCBS, Aetna, Cigna, UHC, and Humana
  • Klinic handles all prior authorization—patient never manages PA paperwork
  • Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) at full clinical doses with home delivery
  • Named clinical leadership (CMO Dr. Saba Haq, Chief Physician Dr. Vivek Chander) and disclosed founder

Where it loses points

  • Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
  • No compounded semaglutide or tirzepatide option for patients seeking lower-cost alternatives
  • Medication cost is separate from visit fees ($99 initial, $75 follow-up) — total self-pay cost is higher
  • No labs or dedicated nutrition/coaching program included in any plan
  • Pharmacy fulfillment via Klinic Pharmacy Hub Services LLC (non-dispensing hub); actual dispensing is third-party
Revive Meds

Graded #404 · C

Strengths

  • Offers both compounded semaglutide and dual-agonist tirzepatide, each combined with vitamin B12 (cyanocobalamin) in a single injection
  • Pay-per-order model with no subscription, sign-up fees, or long-term commitment, and free shipping on every order
  • Names its six 503A compounding pharmacies and two prescribing physicians, which is unusually transparent on fulfillment
  • Available in all 50 states and HSA/FSA eligible through a Medical Necessity Letter
  • Prepaying 3 to 12 months cuts the effective cost to as low as $202/mo (semaglutide) or $300/mo (tirzepatide)

Where it loses points

  • Month-to-month pricing is steep: $369/mo semaglutide and $459/mo tirzepatide unless you prepay several months
  • No public price list; pricing appears only after you complete a full health intake and create an account
  • Not LegitScript-certified (no seal displayed on the site)
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard